It's no more rational to ignore the value of success than it is to ignore the risk of failure.
I am not ignoring the value of success - quite the contrary my suggestion is that people and companies innately tend to put too much focus on this. It is unbalanced. Therefore a concious effort needs to be made to look at the negative (there is actually a whole field of risk management that is a version of this). I guess I could do as my wife suggests - if you are going to say something negative also try to say something encouraging. I try - but I guess I need to work on it more -g-. Seriously - I like the management. At the very least they don't make the obvious gaffes of other management teams. But I still have more calibration to do.
There I disagree strongly. Starving companies of cash can cripple them for good. So it turns out not to be an opportunity for you or anyone else.
Agree completely with the moral point. I was making the more practical (and self centered) point that the shorts seem to short indescriminantly - even stocks where management has a record of good fiscal management. So shorting provides deals I wouldn't otherwise get.
The whole debate on Repros for the past couple of weeks has been entirely one-sided in focusing on the risk of the anemia trial missing.
Agree that focusing on the anemia trial is a little overdone - but suggest it is not completely overdone given Repros' need for cash. 6-9 (?)months of additional delay waiting for UF trial data is a lot of additional time with the cash at hand.
Market Data 
Markets 
AI
